Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Why we need animal models
3. Maximal electroshock seizure (MES) test
4. PTZ seizure test
5. Discovery of new AEDs
6. Models of epilepsy or epileptic seizures
7. Models for specific types of epilepsy
8. The kindling model of temporal lobe epilepsy
9. Anticonvulsant spectrum of AEDs
10. Other indications of approved AEDs
11. Top 10 therapeutic classes by US sales
12. Discovery of new AEDs - conclusions
13. Animal testing models and antiepileptic drugs
14. Specific models for pharmacoresistant seizures
15. Animal models of drug-resistant epilepsy
16. AED responders vs. non-responders
17. Mechanisms of drug resistance in epilepsy
18. The NIH anticonvulsant screening project
19. Evaluating changes in new AEDs efficacy
20. Efficacy of new AEDs during chronic treatment
21. Adverse effects of AED (epileptic/non-epileptic) (1)
22. Adverse effects of AED (epileptic/non-epileptic) (2)
23. Estimating effective AED plasma concentration (1)
24. Estimating effective AED plasma concentration (2)
25. Antiepileptogenic/disease-modifying treatments
26. Epilepsy development, progression, intervention
27. Testing antiepileptogenic drug potential
28. Future goals for therapeutic intervention
29. Using antiepileptic drugs for antiepileptogenesis
30. Therapeutic intervention - rational strategies
31. Rational strategies for antiepileptogenesis
32. GABA receptors during epileptogenesis-excitatory
33. Modification of epileptogenesis by Bumetanide
34. Summary
35. Acknowledgments

Topics Covered

• Diverse models available
• Invaluable preclinical approach for discovery of new treatments for epilepsy
• Specific models for pharmacoresistant seizures
• Models for the discovery of epilepsy-preventing drugs

Links

Series:

• Animal Models in Biomedical Research
• Epilepsy and Seizures

Categories:

• Methods
• Neuroscience

Therapeutic Areas:

• Neurology

Talk Citation

Publication History

• Published on July 13, 2011
• Reviewed on January 13, 2025

Financial Disclosures

• Dr. Wolfgang Löscher has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.